NIH Study: Oral GLP-1 Drugs May Suppress Addiction Cravings by Targeting Brain's Reward System

A National Institutes of Health-funded study has identified a previously unknown mechanism by which a new class of oral GLP-1 weight-loss medications suppress cravings, potentially opening the door to treatments for substance use disorders beyond their current applications for obesity and diabetes.

Published in Nature on May 6, 2026, the research from the University of Virginia reveals that small-molecule GLP-1 receptor agonists—oral drugs like orforglipron recently approved by the FDA—penetrate deeper into the brain than their injectable counterparts to modulate reward circuits associated with desire and compulsive behavior.

A New Neural Pathway for Craving Suppression

Scientists have long understood that larger peptide GLP-1 drugs such as semaglutide (Ozempic, Wegovy) suppress appetite by engaging networks in the hypothalamus and hindbrain. What remained unclear was how the newer small-molecule formulations achieved their effects, and whether they might influence behaviors beyond eating.

The research team, led by Ali Guler, Ph.D., used gene-editing techniques to modify mouse GLP-1 receptors to more closely resemble human biology. When they administered orforglipron and danuglipron, they observed activity not only in expected appetite-regulation regions but also in the central amygdala—a deeper brain structure previously thought inaccessible to GLP-1 medications.

"We've known that GLP-1 drugs suppress feeding behavior driven by energy demand," Guler explained. "Now it seems oral small-molecule GLP-1s also dial back eating for pleasure by engaging a brain reward circuit."

The central amygdala plays a critical role in processing desire and reward-seeking behavior. Once activated by the GLP-1 drugs, this region reduced dopamine release into key hubs of the brain's reward circuitry during hedonic feeding—eating motivated by pleasure rather than hunger.

From Food Cravings to Substance Use

The implications extend far beyond weight management. Because substance use disorders fundamentally involve dysregulated reward processing and compulsive craving, the discovery suggests these medications might similarly dampen drug-seeking behavior.

"As the accessibility of these medications continues to rise and patient uptake increases, it's crucial that we understand the neural mechanisms underlying the effects we're seeing," said Lorenzo Leggio, M.D., Ph.D., clinical director of NIH's National Institute on Drug Abuse (NIDA).

The research arrives amid growing evidence linking GLP-1 medications to reduced addiction risk. A separate large-scale study published in The Lancet Psychiatry in March 2026 analyzed nearly 100,000 individuals using Swedish national health registers and found that semaglutide users experienced a 47% reduction in hospital care and work absence related to substance use disorders compared to periods without treatment.

That study also documented significant mental health benefits: psychiatric hospital visits dropped by 42%, depression risk fell 44%, and anxiety disorders decreased 38% during GLP-1 treatment periods.

The Promise of Oral Formulations

Unlike injectable GLP-1 drugs that require weekly subcutaneous administration, small-molecule formulations like orforglipron can be taken as daily pills. This distinction matters for accessibility and patient adherence, particularly in addiction treatment settings where medication compliance often determines outcomes.

The oral formulations are also cheaper to manufacture, potentially expanding access to populations that have historically faced barriers to expensive biologic medications. With over 1.5 million Americans using compounded GLP-1 drugs as of January 2026, according to manufacturer data, the public health implications of understanding these medications' full neurological effects are substantial.

Next Steps for Addiction Research

The University of Virginia team has already outlined follow-up studies to investigate whether small-molecule GLP-1s can specifically reduce cravings for substances beyond food. With 33 active clinical trials already registered for GLP-1 medications in substance use disorders—including Phase 2 work for opioid use disorder at Penn State Hershey Medical Center—the pipeline is expanding rapidly.

The NIH supported the current research through multiple institutes, including the National Institute on Drug Abuse, National Institute of Neurological Disorders and Stroke, and National Institute of General Medical Sciences—reflecting federal recognition of the potential cross-over between metabolic and addiction neuroscience.

Clinical and Policy Considerations

While the findings are promising, researchers emphasize that this was a preclinical study in mice, not a human clinical trial. The FDA has not assessed these medications for addiction treatment indications, and any off-label use for substance use disorders would require careful clinical oversight.

Nevertheless, the identification of a specific neural mechanism—reduced dopamine release in reward circuits via central amygdala activation—provides a biological rationale that could accelerate drug development. For a field that has seen only modest advances in pharmacological treatments for addiction over the past two decades, the emergence of a new mechanistic pathway represents genuine progress.

The research also highlights the importance of continued federal investment in basic neuroscience. The NIH funding that supported this discovery comes at a moment of uncertainty for federal science budgets, with proposed restructuring of health agencies potentially affecting the pipeline of addiction research.

As policymakers debate the future of national drug strategy, studies like this demonstrate how fundamental research into brain reward systems can yield unexpected therapeutic possibilities—transforming medications developed for one condition into potential treatments for some of the most challenging disorders in medicine.